Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Workman

Showing results (241-250 of 315) with videos related to

Pageof 32
Sort By:
Molecular Cancer Therapeutics|May 5, 2012
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancerCraig P Carden, Adam Stewart, Parames Thavasu, et al.
Cancer Research|December 24, 2011
Histone deacetylase inhibition increases levels of choline kinase α and phosphocholine facilitating noninvasive imaging in human cancersMounia Beloueche-Babari, Vaitha Arunan, Helen Troy, et al.
Nucleic Acids Research|November 21, 2020
canSAR: update to the cancer translational research and drug discovery knowledgebaseCostas Mitsopoulos, Patrizio Di Micco, Eloy Villasclaras Fernandez, et al.
Oncotarget|July 21, 2016
Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumorsLynsey Vaughan, Paul A Clarke, Karen Barker, et al.
Molecular Cell|December 31, 2002
Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1Barry Panaretou, Giuliano Siligardi, Philippe Meyer, et al.
Molecular Cancer Therapeutics|June 11, 2009
Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumorsRichard D Baird, Jos Kitzen, Paul A Clarke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2011
A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumorsSimon Pacey, Richard H Wilson, Mike Walton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202Florence I Raynaud, Steven R Whittaker, Peter M Fischer, et al.
Nature Chemical Biology|December 15, 2012
A public-private partnership to unlock the untargeted kinomeStefan Knapp, Paulo Arruda, Julian Blagg, et al.
Cancer Research|July 24, 2015
Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug ResistanceMark D Gurden, Isaac M Westwood, Amir Faisal, et al.
Pageof 32

Showing results (241-250 of 315) with videos related to

Sort By:
Pageof 32
Molecular Cancer Therapeutics|May 5, 2012
The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancerCraig P Carden, Adam Stewart, Parames Thavasu, et al.
Cancer Research|December 24, 2011
Histone deacetylase inhibition increases levels of choline kinase α and phosphocholine facilitating noninvasive imaging in human cancersMounia Beloueche-Babari, Vaitha Arunan, Helen Troy, et al.
Nucleic Acids Research|November 21, 2020
canSAR: update to the cancer translational research and drug discovery knowledgebaseCostas Mitsopoulos, Patrizio Di Micco, Eloy Villasclaras Fernandez, et al.
Oncotarget|July 21, 2016
Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumorsLynsey Vaughan, Paul A Clarke, Karen Barker, et al.
Molecular Cell|December 31, 2002
Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1Barry Panaretou, Giuliano Siligardi, Philippe Meyer, et al.
Molecular Cancer Therapeutics|June 11, 2009
Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumorsRichard D Baird, Jos Kitzen, Paul A Clarke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2011
A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumorsSimon Pacey, Richard H Wilson, Mike Walton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202Florence I Raynaud, Steven R Whittaker, Peter M Fischer, et al.
Nature Chemical Biology|December 15, 2012
A public-private partnership to unlock the untargeted kinomeStefan Knapp, Paulo Arruda, Julian Blagg, et al.
Cancer Research|July 24, 2015
Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug ResistanceMark D Gurden, Isaac M Westwood, Amir Faisal, et al.
Pageof 32